RhumbLine Advisers’s ADC Therapeutics ADCT Stock Holding History

RhumbLine Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$126K	Buy	117,364 +13,313	+13%	+$38.8K	﹤0.01%	3452
2026 Q1	$390K	Buy	104,051 +13,368	+15%	+$52.7K	﹤0.01%	2758
2025 Q4	$320K	Sell	90,683 -9,791	-10%	-$39.7K	﹤0.01%	2934
2025 Q3	$402K	Sell	100,474 -2,134	-2%	-$6.73K	﹤0.01%	2837
2025 Q2	$275K	Sell	102,608 -9,021	-8%	-$19K	﹤0.01%	3047
2025 Q1	$157K	Buy	111,629 +1,592	+1%	+$2.71K	﹤0.01%	3223
2024 Q4	$219K	Buy	110,037 +14,848	+16%	+$38.9K	﹤0.01%	3147
2024 Q3	$300K	Buy	95,189 +9,212	+11%	+$29.1K	﹤0.01%	3024
2024 Q2	$272K	Buy	+85,977	New	+$342K	﹤0.01%	3059

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RhumbLine Advisers's ADCT Position: Q2 2026 in Review

RhumbLine Advisers increased its ADC Therapeutics (ADCT) stake by 13% in Q2 2026, buying an estimated $38.8K and bringing the position to 117,364 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #3452.

RhumbLine Advisers first reported a position in ADCT in Q2 2024 and has held it in 9 quarters since. The position peaked at $402K in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

RhumbLine Advisers held 117,364 shares of ADC Therapeutics worth $126K as of Q2 2026.
RhumbLine Advisers bought 13,313 ADC Therapeutics shares in Q2 2026, an estimated $38.8K.
ADC Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3452 holding.
RhumbLine Advisers first reported a position in ADC Therapeutics in Q2 2024 and has held it in 9 quarters since.
RhumbLine Advisers's ADC Therapeutics position peaked at $402K in Q3 2025.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.